Recent studies have demonstrated that the RAS/MAPK pathway is the most frequently mutated pathway in patients with cancer, with driver mutations in NRAS or KRAS occurring in 40 to 55% of newly diagnosed patients [9]. The gene discussed is KRAS; the disease is cancer.